A Phase III result in a younger age group

In a Phase III trial of 165 children ages 6 to under 12 with obesity, 40.4% of those assigned to weekly semaglutide plus lifestyle support moved below the obesity threshold after 68 weeks, compared with none assigned to placebo plus the same support. Reuters reported the September 7 result, and Novo Nordisk said its multinational STEP Young study also produced a greater reduction in body mass index than placebo. The finding extends evidence for a widely used obesity medicine into an age group with few drug options. It is not an approval decision or a complete scientific report.

The company said more than 85% of participants entered the trial with class II or class III severe obesity. Both groups received a reduced-calorie diet and increased physical activity, testing whether semaglutide added benefit to shared lifestyle support. According to the topline release, maximum weekly doses were 1.7 or 2.4 milligrams, based on starting weight. Novo reported no new concerns involving growth or pubertal development.

Those are important signals, but the public evidence is incomplete. Novo did not disclose the average BMI change, confidence intervals, dropout rates, serious adverse events or gastrointestinal side-effect rates. Detailed findings are scheduled for ObesityWeek in Washington from November 14 through 17. Until then, the headline result remains a company-reported estimate rather than a fully scrutinized trial account.

What the 40.4% figure means

Weight categories for growing children are not defined by the fixed adult BMI cutoffs. STEP Young used age- and sex-specific U.S. growth charts, under which obesity begins at the 95th BMI percentile. Severe obesity is commonly defined as at least 120% of that percentile, as the latest CDC report explains. Moving below the obesity threshold therefore means moving into an overweight or normal-weight percentile category; it does not necessarily mean reaching a normal-weight category.

The 40.4% estimate came from what Novo called the “trial product estimand,” an analysis estimating the effect if children adhered to treatment. It answers a useful efficacy question but differs from an estimate incorporating interruptions or discontinuations likely in routine care. The company has not released a corresponding treatment-policy analysis or the participant counts behind the rounded percentage.

The registered trial record describes STEP Young as randomized, double-blind and placebo-controlled, reducing several important forms of bias. Its principal assessment is change in BMI at week 68, with additional measures extending beyond that period. The relatively small sample and limited follow-up constrain what the study can establish about rare harms, long-term development and durability after treatment ends.

Why the result matters

Childhood obesity is a chronic disease shaped by biology, environment, food access, physical activity and socioeconomic conditions. The WHO estimates that more than 160 million people ages 5 to 19 were living with obesity in 2022, up from 31 million in 1990. U.S. data from August 2021 through August 2023 found obesity in 21.1% of children and adolescents ages 2 to 19, including severe obesity in 7%.

The medical stakes begin well before adulthood. Obesity in childhood is associated with hypertension, abnormal lipids, insulin resistance, sleep apnea, orthopedic problems and psychosocial burdens, and it often persists later in life. At the same time, treatment must avoid stigma and recognize that body size alone does not describe a child’s health. A careful clinical assessment considers growth pattern, comorbidities, family circumstances, mental health, nutrition and the child’s own experience rather than reducing care to a number on a scale.

The American Academy of Pediatrics recommends prompt, family-centered treatment instead of watchful waiting. Its clinical guideline identifies intensive health behavior and lifestyle treatment as foundational and says clinicians may consider weight-loss pharmacotherapy for some children ages 8 through 11, according to a medicine’s indication, risks and benefits. It also says medication should be an adjunct to behavioral care, not a stand-alone substitute. STEP Young’s design reflects that principle because every participant received lifestyle intervention.

A regulatory gap below age 12

Semaglutide is already established for chronic weight management in adults and adolescents, but its U.S. authorization stops at age 12. The current FDA label says the safety and effectiveness of Wegovy have not been established for weight reduction in children younger than 12. That makes STEP Young potentially relevant to a future request to broaden the label, but Novo’s announcement did not specify a filing date and regulators will evaluate the complete dataset, not the topline percentage alone.

There is precedent for testing a GLP-1 medicine in this age range. A randomized trial of daily liraglutide in children ages 6 to under 12, published in NEJM, found a larger BMI reduction than placebo after 56 weeks. No medication was then approved in the United States for common, nonsyndromic obesity below age 12. STEP Young tests a related drug given once weekly, still requiring injection, dose escalation and monitoring.

Approval would require a benefit-risk judgment specific to younger children. The adolescent Wegovy trial recorded nausea in 42% of treated participants, vomiting in 36% and gallstones in 3.8%, according to the FDA label, although rates in STEP Young have not yet been disclosed. Known warnings also address pancreatitis, gallbladder disease, kidney injury related to dehydration, severe gastrointestinal reactions and a boxed warning involving thyroid C-cell tumors observed in rodents. Those risks do not predict the outcome of the younger-child review, but they explain why a general statement that safety was “consistent” cannot replace detailed event tables.

Access, adherence and long-term evidence

Even a favorable regulatory decision would not settle how the medicine should be used. A weekly injection can burden children and caregivers, and an adult study documented substantial weight regain after semaglutide withdrawal. Pediatric care must account for growth, puberty, nutrition, mental health and possibly years of exposure. STEP Young’s 68-week primary result establishes more than a short-term change but cannot answer lifetime questions.

Use has already moved faster than formal indications in some U.S. practices. A recent prescribing study covering more than 3.5 million children ages 8 to 11 with obesity and without diabetes found a sharp rise in GLP-1 prescriptions between 2019 and 2026. That pattern heightens the need for clear evidence, specialist support and transparent discussion of off-label use. It does not establish that such prescribing is appropriate for any particular child.

Cost and insurance coverage may become as consequential as efficacy. Intensive behavioral programs are unevenly available, while branded GLP-1 medicines can be expensive and coverage varies by plan and jurisdiction. Families with the greatest obesity burden may have the least access to multidisciplinary programs, reliable transportation or healthy food. A medicine can expand the treatment toolkit without correcting those structural constraints, and an equitable approach will have to address both clinical access and the environments that shape health.

What comes next

The next substantive checkpoint is the full STEP Young presentation in November. Clinicians and regulators will look for the absolute and percentage BMI changes in both groups, results under analyses that include treatment discontinuation, cardiometabolic measures, body-composition data, adverse events, pubertal assessments and the number of children who completed treatment. They will also need to see whether benefits were consistent across starting weights, ages, sexes and geographic groups without overinterpreting small subgroups.

Longer follow-up will matter just as much. The registry indicates that the program includes assessments beyond week 68, creating an opportunity to examine sustained effects and later safety. Independent peer review will allow specialists to test whether the statistical methods, missing-data assumptions and outcome definitions support the company’s interpretation. A regulatory submission, if Novo makes one, would add a deeper review of manufacturing, dosing and benefit-risk evidence.

For now, STEP Young offers a significant but bounded conclusion: semaglutide added to lifestyle support lowered BMI more than lifestyle support with placebo in a controlled trial of children ages 6 to under 12, and about two in five treated participants moved below the obesity cutoff under an adherence-based analysis. The finding could open a new treatment option for children with severe disease, but it should not be treated as permission for unsupervised use or as evidence that medication displaces family-centered care. The unanswered safety, durability and access questions are part of the result’s meaning, not footnotes to it.